What is 'Keppra rage' and how common is it?

'Keppra rage' refers to behavioral side effects including irritability, aggression, emotional lability, and mood instability associated with levetiracetam. It affects approximately 10-15% of patients and can be significant enough to require dose reduction or switching to a different anticonvulsant. Family members may notice changes before the patient does. Vitamin B6 supplementation may help. Report any behavioral changes to your neurologist promptly.

How quickly can levetiracetam control seizures?

Levetiracetam can reach therapeutic levels quickly and seizure reduction may begin within the first 1-2 weeks of reaching an effective dose. The 2-week titration schedule means you may reach a therapeutic dose in 2-4 weeks. Full assessment of seizure control typically requires 3 months at the target dose.

Does levetiracetam cause liver damage?

Levetiracetam is not metabolized by the liver (unlike many other anticonvulsants) and does not cause liver damage. This is one of its major advantages — it does not interact with medications metabolized by liver enzymes, and liver monitoring requirements are minimal compared to drugs like valproate or carbamazepine. It is cleared by the kidneys.

Can women take levetiracetam during pregnancy?

Levetiracetam is considered to have a lower teratogenicity risk than older anticonvulsants (valproate, phenobarbital, phenytoin), though no anticonvulsant is completely risk-free. The EURAP registry suggests levetiracetam has a lower major malformation rate than many alternatives. Women with epilepsy should discuss medication plans with their neurologist before conception.

What to Expect When Starting Levetiracetam

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Levetiracetam (Keppra) is an anticonvulsant used as monotherapy or adjunctive therapy for focal (partial) seizures, juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures. It has a favorable pharmacokinetic profile (no liver enzyme induction, minimal drug interactions) and can be rapidly titrated to effective doses. A significant side effect — particularly concerning — is behavioral changes including irritability, aggression, and depression, sometimes called 'Keppra rage.'

Week-by-week timeline

Week 1-2

Starting Levetiracetam

Levetiracetam is typically started at 500 mg twice daily and can be titrated every 2 weeks. Common early side effects include somnolence (drowsiness), dizziness, headache, and GI symptoms. Behavioral side effects (irritability, emotional lability, aggression) can appear early and should be reported promptly.

Week 2-4

Dose Titration

Dose is increased every 2 weeks toward the target (typically 1000-3000 mg/day in adults, 750-1500 mg/day in children). Seizure monitoring continues throughout titration. Some patients see seizure reduction at 1000 mg/day; others require higher doses.

Month 1

Assessing Seizure Control

Track seizure type, frequency, and severity in a seizure diary. Share this log with your neurologist. A meaningful reduction in seizure frequency should be apparent at the therapeutic dose. Behavioral side effects should be reported and assessed.

Month 1-3

Behavioral Monitoring Period

Behavioral effects (irritability, aggression, mood changes, suicidal ideation) are most likely to appear in the first 3 months. Family members or caregivers should monitor for personality changes. Supplemental vitamin B6 (pyridoxine) has been used off-label to reduce behavioral side effects.

Month 2-3

Stable Seizure Management

A stable, well-tolerated dose providing optimal seizure control should be established. Periodic kidney function monitoring is recommended as levetiracetam is renally cleared. Annual liver and complete blood count monitoring is also typical.

When to call your doctor

Contact your healthcare provider if you experience:

Thoughts of self-harm or suicidal ideation (FDA warning for anticonvulsants)
Significant personality changes: unusual aggression, irritability, or rage that causes harm to self or others
Worsening seizures or new seizure types
Severe allergic reaction: rash, blistering, fever (rare Stevens-Johnson syndrome)
Unusual bruising or signs of infection (rare blood cell effects)
Coordination problems causing falls (ataxia)
Signs of kidney problems if on high doses: decreased urine output, swelling

Tips for getting started

Take levetiracetam at the same times twice daily — consistency is important for seizure control. Take with food to reduce GI side effects. Never stop levetiracetam abruptly — this can precipitate breakthrough seizures or status epilepticus. Taper under your neurologist's guidance. Keep a seizure diary. Inform your neurologist immediately of any personality or behavioral changes — do not wait for the next scheduled visit. Family members and caregivers should be aware of 'Keppra rage' and monitor for signs. Consider supplemental vitamin B6 as discussed with your neurologist.

Frequently asked questions

More about Levetiracetam

Levetiracetam drug guideSide effects, dosage, interactions, and more Topiramate vs LevetiracetamCompare these medications Lamotrigine vs LevetiracetamCompare these medications Levetiracetam & TopiramateInteraction details

References

[Regulatory] FDA Label: Keppra (levetiracetam) Tablets and Oral Solution https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s067lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Levetiracetam https://medlineplus.gov/druginfo/meds/a699059.html Accessed 2026-03-01.
[Regulatory] AAN Epilepsy Guidelines: Anticonvulsant Selection https://www.aan.com/Guidelines/Home/ByTopic?topicId=21 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026